Department of Pediatrics, Amsterdam UMC, Vrije Universiteit, University of Amsterdam Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, 3584 CH Utrecht, The Netherlands.
Nutrients. 2021 May 13;13(5):1645. doi: 10.3390/nu13051645.
Since the outbreak of coronavirus disease 2019 (COVID-19), many put their hopes in the rapid availability of effective immunizations. Human milk, containing antibodies against syndrome coronavirus 2 (SARS-CoV-2), may serve as means of protection through passive immunization. We aimed to determine the presence and pseudovirus neutralization capacity of SARS-CoV-2 specific IgA in human milk of mothers who recovered from COVID-19, and the effect of pasteurization on these antibodies.
This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Human milk and serum samples were collected. To assess the presence of SARS-CoV-2 antibodies we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein (specific for IgA and IgG), receptor binding domain (RBD) and nucleocapsid (N) protein for IgG in serum, and bridging ELISA with the SARS-CoV-2 RBD and N protein for specific Ig (IgG, IgM and IgA in human milk and serum). To assess the effect of pasteurization, human milk was exposed to Holder (HoP) and High Pressure Pasteurization (HPP).
Human milk contained abundant SARS-CoV-2 antibodies in 83% of the proven cases and in 67% of the suspected cases. Unpasteurized milk with and without these antibodies was found to be capable of neutralizing a pseudovirus of SARS-CoV-2 in (97% and 85% of the samples respectively). After pasteurization, total IgA antibody levels were affected by HoP, while SARS-CoV-2 specific antibody levels were affected by HPP. Pseudovirus neutralizing capacity of the human milk samples was only retained with the HPP approach. No correlation was observed between milk antibody levels and neutralization capacity.
Human milk from recovered COVID-19-infected mothers contains SARS-CoV-2 specific antibodies which maintained neutralization capacity after HPP. All together this may represent a safe and effective immunization strategy after HPP.
自 2019 年冠状病毒病(COVID-19)爆发以来,人们寄希望于快速获得有效的疫苗。含有针对综合征冠状病毒 2(SARS-CoV-2)抗体的人乳可能通过被动免疫提供保护。我们旨在确定从 COVID-19 中康复的母亲的人乳中是否存在针对 SARS-CoV-2 的特异性 IgA 以及其假病毒中和能力,以及巴氏消毒对这些抗体的影响。
本前瞻性病例对照研究纳入了从(疑似)COVID-19 中康复的哺乳期母亲和健康对照者。采集人乳和血清样本。为了评估 SARS-CoV-2 抗体的存在,我们使用了多种互补的检测方法,即 ELISA 法检测血清中 SARS-CoV-2 刺突蛋白(针对 IgG 和 IgA)、受体结合域(RBD)和核衣壳(N)蛋白,以及用于 IgG 的 SARS-CoV-2 RBD 和 N 蛋白的桥接 ELISA,用于检测特异性 Ig(人乳和血清中的 IgG、IgM 和 IgA)。为了评估巴氏消毒的影响,人乳分别接受了 Holder(HoP)和高压巴氏消毒(HPP)处理。
在确诊病例和疑似病例中,83%和 67%的人乳中含有丰富的 SARS-CoV-2 抗体。未经巴氏消毒的含有和不含有这些抗体的人乳均能中和 SARS-CoV-2 假病毒(分别在 97%和 85%的样本中)。巴氏消毒后,HoP 影响总 IgA 抗体水平,而 HPP 影响 SARS-CoV-2 特异性抗体水平。只有 HPP 方法才能保留人乳样本的假病毒中和能力。人乳抗体水平与中和能力之间未观察到相关性。
从感染 COVID-19 康复的母亲的人乳中含有 SARS-CoV-2 特异性抗体,经 HPP 处理后仍保持中和能力。总的来说,HPP 后,这可能代表一种安全有效的免疫策略。